Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
NCT04419649
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)
- NCT04419649 ↗
- Recruiting
- Takeda
- Focused
We haven't built an HCP commentary report on NCT04419649 (elritercept (KER-050) in anemia in very-low/low/intermediate-risk myelodysplastic syndromes) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT04419649 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| YouTube | 2 | |
| X threads | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase 2, Open-Label, Ascending Dose Study of KER-050 for the Treatment of Anemia in Patients With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- Myelodysplastic Syndromes; Cytopenia
- Interventions
- Elritercept
- Arms
- Part 1: Elritercept Cohort 1 · Experimental
- Part 1: Elritercept Cohort 2 · Experimental
- Part 1: Elritercept Cohort 3 · Experimental
- Part 1: Elritercept Cohort 4 · Experimental
- Part 1: Elritercept Cohort 5 · Experimental
- Part 2: Elritercept Dose Confirmation Cohort A · Experimental
- Part 2: Elritercept Dose Confirmation Cohort B · Experimental
- Part 2: Elritercept Dose Confirmation Cohort C · Experimental
- Experimental: Part 2: Elritercept Dose Confirmation Cohort D · Experimental
- Part 2: Elritercept Dose Confirmation Cohort E · Experimental
- Part 2: Elritercept Dose Confirmation Cohort F · Experimental
- Part 2: Elritercept Dose Confirmation Cohort G · Experimental
- Long-term Extension Cohort · Experimental
- Enrollment
- 210 (estimated)
- Primary outcomes
- Number of Participants with Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
- Sponsor
- Takeda
- Start
- Aug 19, 2020
- Primary completion
- Oct 30, 2029 (estimated)
- Results posted
- No
- Registry record
- NCT04419649 · updated Oct 19, 2026